Research
Hormonal
Obesity is a chronic disease characterized by physiological dysregulation of fat mass, not merely a result of willful behavioral choices.
Stop blaming yourself for your weight. Obesity is a chronic disease driven by your body's physiology, not just your willpower. Seek medical treatment because your body is fighting you, and you need professional help to manage it.
StrongSupportsVERY_HIGH confidence
The panel recognized and endorsed the World Health Organization's definition of obesity as a chronic disease characterized by excessive or abnormal adipose tissue that is associated with increased health risk, and reached the consensus that obesity is a disease that develops from a disturbance in the body's normal regulation of fat mass, with development and severity influenced by both endogenous and exogenous (environmental) factors.
Why this rating
Consensus statement by an international panel of obesity medicine experts.
Source
Assessing the state of obesity care: Quality, access, guidelines, and standards
Lee M. Kaplan et al. · Obesity Science & Practice · 2024
DOI 10.1002/osp4.765
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metabolic and bariatric surgery (MBS) is the most effective treatment for obesity and type 2 diabetes, producing superior long-term weight loss and remission rates compared to lifestyle or pharmacologic interventions.Strong
- GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are effective pharmacotherapies for obesity, producing significant weight loss and cardiovascular benefits.Strong
- BMI is an inadequate and potentially harmful sole metric for assessing obesity severity and treatment response.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →